ArticleImmunity & ageing : I & A2015
Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study.
Article in Immunity & ageing : I & A, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of LiveSpo Navax in Treatment of Acute Respiratory Disease in Children Infected With Respiratory Syncytial Virus
Application of LiveSpo Navax® in the Treatment Support of Acute Rhinosinusitis and Acute Otitis Media
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Probiotics and prebiotics as alternatives to antibiotics in aquaculture: a systematic and bibliometric review of antimicrobial and antioxidant mechanisms.Frontiers in microbiology · 2026Pooled it
- Probiotics for preventing acute upper respiratory tract infections.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- Examining the Gastrointestinal and Immunomodulatory Effects of the Novel ProbioticInternational journal of molecular sciences · 2021Trial
- Three Characterized Probiotics from Dairy Sources-Weissella confusa (ProY 5.1), Enterococcus lactis (ProY 5.3), and Leuconostoc lactis (RM 2.1)-Exhibit Potential for Antidiarrheal Effects.Probiotics and antimicrobial proteins · 2026Article
- Bacillus spore probiotics for alleviating functional constipation in children: a randomized, double-blind, placebo-controlled trial.Communications medicine · 2026Article
- Gut-Centric Multi-System Regulation byNutrients · 2026Review
- Multi-Model Longevity Assays Reveal Lifespan- and Healthspan-Promoting Effects ofMicroorganisms · 2026Article
- The Role of Probiotics in Enhancing Animal Health: Mechanisms, Benefits, and Applications in Livestock and Companion Animals.Animals : an open access journal from MDPI · 2025Review
- Evaluating the Compositional Quality of Probiotics Containing Bacillus clausii in India.Advances in therapy · 2025Article
- StreamliningAntibiotics (Basel, Switzerland) · 2025Article
- Article
- EngineeredBioactive materials · 2025Article
- EngineeredACS synthetic biology · 2025Article
- Development of Chitosan-Polyacrylic Acid Complex Systems for Enhanced Oral Delivery ofDrug design, development and therapy · 2025Article
- Bacillus subtilis DE111 partially reverses endothelial dysfunction in western-diet fed mice.Beneficial microbes · 2024Article
- Salivary Immunoglobulin a Alterations in Health and Disease: A Bibliometric Analysis of Diagnostic Trends from 2009 to 2024.Antibodies (Basel, Switzerland) · 2024Article
- Immunosenescence: Aging and Immune System Decline.Vaccines · 2024Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacillus probiotics health benefits have been until now quite poorly studied in the elderly population. This study aimed to assess the effects of Bacillus subtilis CU1 consumption on immune stimulation and resistance to common infectious disease (CID) episodes in healthy free-living seniors.
resultsOne hundred subjects aged 60-74 were included in this randomized, double-blind, placebo-controlled, parallel-arms study. Subjects consumed either the placebo or the probiotic (2.10(9) B. subtilis CU1 spores daily) by short periodical courses of 10 days intermittently, alternating 18-day course of break. This scheme was repeated 4 times during the study. Symptoms of gastrointestinal and upper/lower respiratory tract infections were recorded daily by the subjects throughout the study (4 months). Blood, saliva and stool samples were collected in a predefined subset of the first forty-four subjects enrolled in the study. B. subtilis CU1 supplementation did not statistically significantly decrease the mean number of days of reported CID symptoms over the 4-month of study (probiotic group: 5.1 (7.0) d, placebo group: 6.6 (7.3) d, P = 0.2015). However, in the subset of forty-four randomized subjects providing biological samples, we showed that consumption of B. subtilis CU1 significantly increased fecal and salivary secretory IgA concentrations compared to the placebo. A post-hoc analysis on this subset showed a decreased frequency of respiratory infections in the probiotc group compared to the placebo group.
conclusionTaken together, our study provides evidence that B. subtilis CU1 supplementation during the winter period may be a safe effective way to stimulate immune responses in elderly subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.